Compare Novartis AG (NVS) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Uranium Energy Corp — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Uranium Energy Corp trades at $11.61 (market cap $5.63B). The key difference: Novartis AG is far larger — about 53× Uranium Energy Corp's market cap, and Novartis AG pays a 3.02% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| NVS | UEC | |
|---|---|---|
Market Cap | $298.18B | $5.63B |
Sector | Health | Energy |
52-Week High | $168.62 | $20.14 |
52-Week Low | $119.31 | $9.04 |
Enterprise Value | $339.50B | $5.14B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
UEC trades at $11.26, up 4.65% in the last 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces profitability challenges with a negative net income margin of -513.24%. Recent news highlights optimism around nuclear energy growth, but financial performance remains under pressure.
Outlook is mixed: strong analyst buy ratings (87.5%) and sector tailwinds support potential, but persistent losses, high P/S ratio of 265.97, and execution risks pose significant challenges. Investors should weigh the speculative growth narrative against fundamental weaknesses and cash flow concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
